We are investigating AveXis, Inc. (“AveXis” or the “Company”) (NasdaqGS: AVXS) relating to the sale of the Company to affiliates of Novartis AG (NYSE: NVS). As a result of the merger AveXis shareholders are only anticipated to receive $218 in cash in exchange for each share of AveXis.